Showing results (561-570 of 658) with videos related to
Sort By:
Pageof 66
Neuro-Oncology|February 13, 2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapyJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.Neuro-Oncology Advances|December 8, 2020
Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma WorkshopMarta Penas-Prado, Jing Wu, Daniel P Cahill, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium StudyTimothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.Journal of Neuro-Oncology|October 13, 2006
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiformeMorris D Groves, Vinay K Puduvalli, Susan M Chang, et al.Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.Neuro-Oncology|August 10, 2024
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomasPravesh Gupta, Minghao Dang, Shivangi Oberai, et al.Cancer Discovery|May 27, 2021
Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in GlioblastomaFrancesca Puca, Fei Yu, Caterina Bartolacci, et al.Neuro-Oncology|October 31, 2019
Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomasVictor Ruiz-Rodado, Tathiane M Malta, Tomohiro Seki, et al.Neuro-Oncology|December 21, 2016
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813Susan Chang, Peixin Zhang, J Gregory Cairncross, et al.Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.Pageof 66